Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised,...

Area of Science:

• Hematology-Oncology
• Clinical Trials
• Pharmacology

Background:

• Optimizing anthracycline dosage for diffuse large B-cell lymphoma (DLBCL) requires further investigation.
• This study evaluated R-CEOP70 against R-CHOP50 for non-inferiority and cardiotoxicity, and R-CEOP90 for superior efficacy in DLBCL treatment.

Purpose of the Study:

• To determine if R-CEOP70 is non-inferior to R-CHOP50 in DLBCL treatment with reduced cardiotoxicity.
• To assess if R-CEOP90 offers superior efficacy compared to R-CHOP50 or R-CEOP70 with acceptable toxicity.

Main Methods:

• A multicenter, phase 3, randomized controlled trial (NHL-001) involving newly diagnosed DLBCL or follicular lymphoma grade 3B patients.
• Patients were assigned to R-CHOP50, R-CEOP70, or R-CEOP90 regimens based on age.
• Primary endpoint was 2-year progression-free survival; cardiotoxicity assessed by left ventricular ejection fraction (LVEF) changes.

Main Results:

• R-CEOP70 demonstrated non-inferiority to R-CHOP50 in 2-year progression-free survival (72.4% vs 72.5%) with significantly less cardiotoxicity (13% vs 29% LVEF decrease).
• For young patients, R-CEOP90 significantly improved 2-year progression-free survival (88.8%) compared to R-CHOP50 (75.9%) and R-CEOP70 (77.4%), with increased neutropenia but similar infection rates.
• Fewer patients in R-CEOP70 and R-CEOP90 groups showed LVEF decrease compared to R-CHOP50.

Conclusions:

• R-CEOP70 is a suitable alternative to R-CHOP50 for DLBCL, offering comparable efficacy and reduced long-term cardiotoxicity.
• High-dose epirubicin (R-CEOP90) may benefit young DLBCL patients, warranting consideration despite higher neutropenia rates.
• Epirubicin serves as an effective doxorubicin substitute in R-CHOP regimens with improved cardiac safety.